Molecule News and Research

RSS

Findings shed new light on the molecular mechanisms of visual system in brain

The laboratory of Dr. Fr-d-ric Charron, a researcher at the Institut de recherches cliniques de Montr-al (IRCM), has discovered a new molecular mechanism that permits the guidance of visual nerves towards the brain.

8 Jan 2010

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Elixir Pharmaceuticals, Inc. announced today that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease.

8 Jan 2010

Researchers identify new approach to eliminate side effects of drugs

Researchers at the Stanford University School of Medicine have taken an early step toward identifying a new approach to drug discovery that may eventually yield drugs with fewer side effects.

7 Jan 2010

SDI to discover biomarkers in collaboration with Fred Hutchinson Cancer Research Center

SDI (Strategic Diagnostics Inc.), a provider of biotechnology-based products and services, and Fred Hutchinson Cancer Research Center (the Hutchinson Center) today jointly announced they will collaborate to discover biomarkers for use in the early detection of a variety of cancers.

7 Jan 2010

Study explains how H. pylori infection causes stomach cancer

Researchers report that Helicobacter pylori, the only bacterium known to survive in the harsh environment of the human stomach, directly activates an enzyme in host cells that has been associated with several types of cancer, including gastric cancer.

7 Jan 2010

Ensemble Discovery initiates strategic alliance with Pfizer

Ensemble Discovery today announced the initiation of a strategic alliance with Pfizer Inc. to discover and develop drug candidates of a novel class against a number of high-value pharmaceutical targets.

6 Jan 2010

Innexus Biotechnology designs new psoriasis product

InNexus Biotechnology Inc. (TSX.V: IXS) (www.ixsbio.com), a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the development of a new psoriasis product based on its proprietary dermal permeating Transmab™ technology.

6 Jan 2010

Phase I clinical trial for Intellikine's INK128 inhibitor initiated

Intellikine, Inc. has initiated a Phase I clinical trial for its targeted anticancer drug INK128, a novel orally-available small molecule inhibitor of both the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway.

6 Jan 2010

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody1 drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday).

6 Jan 2010

Annelie Wendeberg presents protocol for identification of environmental microbes

Metagenomics, the study of DNA isolated from samples of naturally occurring microbial populations, is rapidly growing. Improvements to cloning and sequencing techniques are allowing researchers to study microorganisms in environmental samples, and new knowledge of species interactions and community dynamics is emerging.

5 Jan 2010

Scientists develop mucus-penetrating biodegradable nanoparticles to deliver drugs over time

Johns Hopkins University researchers have created biodegradable nanosized particles that can easily slip through the body's sticky and viscous mucus secretions to deliver a sustained-release medication cargo.

5 Jan 2010

Elusive human protein outsmarted

A team of researchers is being recognized for devising a new way to study a human protein that long has evaded close scrutiny by scientists investigating its role in the communication of important genetic messages inside a cell's nucleus to workhorse molecules found elsewhere.

5 Jan 2010

"Nanoworms" and doxorubicin loaded hollow nanoparticles to fight cancer

A team of researchers in California and Massachusetts has developed a "cocktail" of different nanometer-sized particles that work in concert within the bloodstream to locate, adhere to and kill cancerous tumors.

5 Jan 2010

Talampanel slows progression of amyotrophic lateral sclerosis

A drug already used to treat symptoms of epilepsy has potential to slow the muscle weakening that comes with amyotrophic lateral sclerosis (ALS), scientists report after completing a Phase II clinical trial-an early, small-scale test to show if the drug works and continues to be safe.

5 Jan 2010

GIVI scientists discover anti-HIV molecule that enhances infection, reduces transmission

Scientists at the Gladstone Institute of Virology and Immunology (GIVI) have discovered a new agent that might inhibit the infectivity of HIV. The agent, surfen, impairs the action of a factor in semen that greatly enhances the viral infection.

5 Jan 2010

Jamming bacterial communication may improve chronic wound care

Listening in on bacterial conversations could be the solution for improving chronic wound care, says a team of researchers at Binghamton University, State University of New York. Their findings have been published in the Journal of Applied Microbiology.

5 Jan 2010

A 'cocktail' to kill cancerous tumors

5 Jan 2010

Carbon nanotube: A viable alternative for rapid DNA sequencing

Faster sequencing of DNA holds enormous potential for biology and medicine, particularly for personalized diagnosis and customized treatment based on each individual's genomic makeup.

4 Jan 2010

BioInvent International begins BI-505 drug study on patients with advanced multiple myeloma

BioInvent International AB announced today that the first patient has been treated in an open, dose-escalation phase I study of the company’s antibody BI-505 for patients with advanced multiple myeloma.

4 Jan 2010

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

Emerald BioStructures (formerly deCODE biostructures) announced today a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD) to engineer new allosteric small molecule modulators of the enzyme phosphodiesterase-4 (PDE4), with reduced side effects. According to the paper, the researchers established the structural basis of PDE4 regulation through crystal structures of the PDE4 regulatory domain in contact with small molecules.

29 Dec 2009